跳至主要内容
临床试验/NCT03258190
NCT03258190已完成2 期

Lime Powder Regimen Supplement Alleviates Urinary Metabolic Abnormalities to Prevent Urolithiasis Recurrence.

Chulalongkorn University1 个研究点 分布在 1 个国家目标入组 137 人开始时间: 2014年7月1日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
状态
已完成
入组人数
137
试验地点
1
主要终点
Renal stone recurrence

研究概览

简要总结

Lime powder regimen (LPR) is a lime-derived composition enriches with citrate/citric acid and potassium. LPR was invented to treat the renal stone patients with high risk of stone recurrence after stone removal. LPR should have equal or higher efficacy and lower adverse effect than current standard medicine.

详细描述

Lime powder regimen (LPR) is a mixture of lime-derive component with adjuvants containing high concentration of citrate, and moderate amount of potassium, magnesium and antioxidants. LPR was tested and verified to be very less toxic in cell culture and animal models. The clinical trial phase II showed that LPR reduced urinary metabolic abnormalities that enhance stone formation, such as hypocitraturia, hypokaliuria and acidified urine. Adverse effect of LPR was very low.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
Single (Participant)

盲法说明

LPR and Placebo were prepared in the same containers with code that was provided by investigators

入排标准

年龄范围
18 Years 至 65 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Renal stone patients who were identified and stone was removed by surgical method.

排除标准

  • Chronic kidney disease, chronic liver disease, history of coronary artery disease, or person who takes any medication that alters urinary metabolic profiles

研究组 & 干预措施

Lime Powder Regimen

Experimental

Participants were asked to take LPR twice a day for 6 months

干预措施: Lime Powder Regimen (Drug)

Placebo

Placebo Comparator

Participants were asked to take Placebo twice a day for 6 months

干预措施: Lime Powder Regimen (Drug)

结局指标

主要结局

Renal stone recurrence

时间窗: 6 months

The stone recurrence after surgical removal of stone that can be detected by CT scan

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Piyaratana Tosukhowong

Professor

Chulalongkorn University

研究点 (1)

Loading locations...

相似试验